<img alt="" src="https://secure.52enterprisingdetails.com/787780.png" style="display:none;">
Skip to content

Press Release

Aurevia announces strategic split into two independent entities: Aurevia and Labquality

Labquality Days 2026

Welcome to the 50th International Congress on Quality in Laboratory Medicine!

We are Aurevia

Aurevia advances healthcare, pharmaceutical and medical technology development and quality with a future-focused approach, aligned with client needs.

Aurevia

Towards excellence in patient care

As Aurevians, we are the excellence makers: a team of experienced experts in healthcare and health-tech standards and quality. Together, we advance healthcare, pharmaceutical and medical technology development with a future-focused approach, aligned with client needs. Driven by our commitment to care, we contribute quality to the industry and pave the way for safer, more effective patient care worldwide.
Asset 674

Clinical Laboratories

We offer clinical laboratories a wide range of internationally recognised products and services to help them maintain and improve analytical performance.
Asset 694

Pharmaceuticals & Biotech

Our clinical research team provides extensive and high-quality services for pharma and biotech companies.

Asset 679

Medical Devices

Our team of experts serves medical device manufacturers by providing high-quality regulatory and clinical research services for the entire lifecycle of your products.
Asset 675

IVD devices

Clinical research and regulatory affairs services that cover the entire lifecycle of your in vitro diagnostic device.

Latest news

FDA’s new guidance: Computer Software Assurance (CSA) for production and quality system software

FDA’s final guidance on Computer Software Assurance (CSA) for Production and Quality System Software marks a...

Strategic clarity: The new currency in life science

In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking...

The FDA’s new transparency policy (Part 3)

In the third part of our article series on the FDA’s new “radical transparency” initiative, we explore strategic...
Navigating the potential impact of the FDAs new radical transparency

The FDA’s new transparency policy (Part 2)

In the second part of our article series on the FDA’s new “radical transparency” initiative, we explore regulatory...

Labquality Days 2026 Scientific Program Launched!

2026 marks the 50th edition of Labquality Days - one of Northern Europe's largest international congresses in...